Core Viewpoint - Ekso Bionics Holdings, Inc. reported a significant decline in revenue for the second quarter of 2025, primarily due to lower sales of Enterprise Health devices, but anticipates recovery in the second half of the year driven by growth in Personal Health products [3][4]. Financial Performance - For Q2 2025, the company recorded revenue of $2.1 million, down from $5.0 million in Q2 2024, attributed mainly to decreased Enterprise Health device sales [4]. - Gross profit for Q2 2025 was $0.8 million, with a gross margin of approximately 40%, compared to $2.6 million and a gross margin of 53% in Q2 2024 [5]. - The net loss for Q2 2025 was $2.7 million, or $1.24 per share, compared to a net loss of $2.4 million, or $1.99 per share, in Q2 2024 [7][17]. Expenses - Sales and marketing expenses for Q2 2025 were $1.7 million, slightly down from $1.8 million in Q2 2024, mainly due to lower discretionary payroll [6]. - Research and development expenses decreased to $0.9 million in Q2 2025 from $1.1 million in Q2 2024, primarily due to a reduction in headcount [6]. - General and administrative expenses increased to $2.3 million in Q2 2025 from $2.0 million in Q2 2024, attributed to lower allocable costs to manufacturing [7]. Cash Position - As of June 30, 2025, the company had cash and restricted cash totaling $5.2 million, down from $6.5 million at the end of 2024 [8][15]. Strategic Developments - The company named Bionic Prosthetics & Orthotics Group as its first distributor for the Ekso Indego Personal device within the orthotics and prosthetics industry [10]. - Ekso Bionics was accepted into the NVIDIA Connect program, aiming to develop a proprietary foundation model for human motion and integrate AI capabilities across its product portfolio [10]. - The launch of eksoUniversity provides a library of continuing education courses for physical therapists and assistants working with patients with neurological conditions [10].

Core Viewpoint - Ekso Bionics Holdings, Inc. is set to release its financial and business results for Q2 2025 on July 28, 2025, with a conference call scheduled to discuss these results and recent developments [1]. Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility for both medical and industrial applications [3]. - The company focuses on improving health and quality of life through advanced robotics that enhance, amplify, and restore human function [3]. - Ekso Bionics is unique in offering technologies that assist individuals with paralysis to stand and walk, as well as enhancing capabilities in various job sites globally [3]. - The company is headquartered in the San Francisco Bay Area and is publicly traded on the Nasdaq Capital Market under the symbol "EKSO" [3].

Core Insights - Ekso Bionics has launched eksoUniversity, a platform providing continuing education courses for physical therapists and physical therapy assistants, approved for CEUs in over 30 states [1][3][4] Group 1: Company Overview - Ekso Bionics is a leader in exoskeleton technology for medical and industrial applications, focusing on enhancing human strength, endurance, and mobility [4] - The company aims to improve health and quality of life through advanced robotics designed to restore human function [4] Group 2: Product Offering - eksoUniversity offers a growing library of online courses specifically for PTs and PTAs working with patients with neurological conditions [3] - The platform is designed to educate the neurological physical therapy community on relevant topics and evolving treatment options [4] Group 3: Market Context - Continuing education units (CEUs) are required for healthcare professionals to maintain competency in their fields, ensuring they stay updated on treatments and technologies [2]

Company Overview - Ekso Bionics is a developer of exoskeleton solutions designed to augment human strength, endurance, and mobility[6] - The company has deployed over 900 devices in more than 450 centers worldwide[7, 12, 37] Financial Performance & Market Opportunity - Ekso Bionics generated $15.4 million in clinical revenue in 2023, out of $18.2 million total revenue[6] - The company received CMS reimbursement for Ekso Indego Personal at $91,000[7, 50] - The total potential addressable market for personal mobility exoskeletons is estimated at $13.1 billion, including potential future neurodegenerative indications in the USA[55] - The long-term potential market for general debility usage is estimated at $34 billion, based on 1.5 million manual wheelchair users in the USA[55] - The company's revenue for FY 2023 was $18.3 million, a 42% increase compared to $13.0 million in FY 2022[71, 75] Market Reach & Strategy - The company leverages a clinical installed base of approximately 260 US centers to reach patients with spinal cord injuries[7] - Ekso Bionics is focused on achieving positive operating cash flow through scaling revenue growth and improving operating efficiencies[7, 82] - The company is expanding its market reach across the care continuum, from outpatient to home, with the Indego product line[76] - The potential market opportunity for the EVO industrial exoskeleton in targeted segments is greater than $8 billion annually[66]

Core Insights - Ekso Bionics has successfully demonstrated a proof-of-concept for integrating AI capabilities into its exoskeleton devices, specifically targeting both medical and industrial applications [1][3] - The new AI voice agent, named "Ekso Voice Agent," is designed for intelligent control of the legacy EksoNR device and operates on NVIDIA Jetson Orin Nano hardware [2][3] - The company has a substantial data repository with approximately 350,000 patient sessions and over 15 million data points, which is increasing by an average of 60,000 patient steps daily, positioning it well to leverage AI in exoskeleton technology [3] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility across various applications [5] - The company focuses on improving health and quality of life through advanced robotics, catering to individuals with paralysis and enhancing capabilities in industrial settings [5] - Ekso Bionics is headquartered in the San Francisco Bay Area and is publicly traded on the Nasdaq under the symbol "EKSO" [5] NVIDIA Connect Program - The company has been accepted into the NVIDIA Connect Program, which aims to accelerate product development and enhance cost efficiency for technology companies [4] - Members of this program receive specialized training, priority engineering support, and access to NVIDIA's advanced development kits and GPU platforms [4]

Core Insights - Ekso Bionics has successfully demonstrated a proof-of-concept for integrating AI capabilities into its exoskeleton devices, enhancing user interaction and control [1][3] - The new AI voice agent, named "Ekso Voice Agent," is designed for intelligent control of the EksoNR device and operates on NVIDIA Jetson Orin Nano hardware [2][3] - The company has a substantial data repository with approximately 350,000 patient sessions and over 15 million data points, which is growing by an average of 60,000 patient steps daily, positioning it well to leverage AI in exoskeleton technology [3] Company Overview - Ekso Bionics is a leader in developing exoskeleton solutions aimed at enhancing human strength, endurance, and mobility for both medical and industrial applications [5] - The company focuses on improving health and quality of life through advanced robotics, offering technologies that assist individuals with paralysis and enhance capabilities in various job sites [5] - Ekso Bionics is headquartered in the San Francisco Bay Area and is publicly traded on the Nasdaq under the symbol "EKSO" [5] NVIDIA Connect Program - The NVIDIA Connect Program is designed to accelerate product development for technology companies, providing specialized training, engineering support, and access to advanced development kits and GPU platforms [4] - Membership in this program is expected to help Ekso Bionics deliver next-generation solutions in AI and high-performance computing [4]

Core Points - Ekso Bionics Holdings, Inc. has updated the effective date of its reverse stock split from May 27, 2025, to June 2, 2025, at a ratio of 1-for-15 [1] - The number of outstanding shares will decrease from approximately 35.5 million to about 2.4 million post-split [2] - The reverse stock split was approved by stockholders to raise the per share trading price and regain compliance with Nasdaq's minimum bid price requirement of $1.00 for ten consecutive trading days [3] Summary by Sections Reverse Stock Split Details - The reverse stock split will not result in fractional shares; any fractional shares will be rounded up to the next whole share [4] - All issued and outstanding shares will be affected, reducing the number of shares issuable upon the exercise of stock options and increasing respective exercise prices [5] Stockholder Information - Stockholders holding shares electronically will not need to take action as their shares will be automatically adjusted [6] - Shareholders with physical certificates can contact VStock Transfer, LLC for information on exchanging their certificates [6] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility in medical and industrial applications [7]

Core Points - Ekso Bionics Holdings, Inc. will implement a reverse stock split at a ratio of 1-for-15, effective May 27, 2025 [1][3] - The number of outstanding shares will decrease from approximately 35,289,695 to about 2,352,646 post-split [2] - The reverse stock split aims to raise the per share trading price to comply with Nasdaq's minimum bid price requirement of $1.00 for ten consecutive trading days [3] Shareholder Impact - No fractional shares will be issued; any fractional shares will be rounded up to the next whole share [4] - The reverse stock split will uniformly affect all shareholders without significantly altering their percentage interest in the company's equity [5] - Stock options and restricted stock units will be adjusted accordingly, with a corresponding increase in exercise prices [5] Administrative Details - Shareholders holding shares electronically will not need to take action as their shares will be automatically adjusted [6] - Shareholders with physical certificates can contact VStock Transfer, LLC for information on exchanging their certificates [6] - Additional information regarding the reverse stock split is available in the Company's Definitive Proxy Statement filed with the SEC [6] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility in medical and industrial applications [7] - The company focuses on improving health and quality of life through advanced robotics designed to restore human function [7] - Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO" [7]

Company unveils a strategic initiative to build the world’s first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics’ proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced ...

Company Performance - Ekso Bionics reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.11, and an improvement from a loss of $0.20 per share a year ago, indicating a negative earnings surprise of -9.09% [1] - The company posted revenues of $3.38 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 28.95%, and down from $3.76 million in the same quarter last year [2] - Over the last four quarters, Ekso Bionics has not surpassed consensus EPS or revenue estimates [2] Stock Outlook - Ekso Bionics shares have declined approximately 20.8% since the beginning of the year, compared to a decline of -3.3% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $6.32 million, and for the current fiscal year, it is -$0.25 on revenues of $23.99 million [7] - The estimate revisions trend for Ekso Bionics is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Ekso Bionics belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]